beta-Lactamases are the main cause of bacterial resistance to penicill
ins, cephalosporins and related beta-lactam compounds. These enzymes i
nactivate the antibiotics by hydrolysing the amide bond of the beta-la
ctam ring. Class A beta-lactamases are the most widespread enzymes and
are responsible for numerous failures in the treatment of infectious
diseases. The introduction of new beta-lactam compounds, which are mea
nt to be 'beta-lactamase-stable' or beta-lactamase inhibitors, is thus
continuously challenged either by point mutations in the ubiquitous T
EM and SHV plasmid-borne beta-lactamase genes or by the acquisition of
new genes coding for beta-lactamases with different catalytic propert
ies. On the basis of the X-ray crystallography structures of several c
lass A beta-lactamases, including that of the clinically relevant TEM-
1 enzyme, it has become possible to analyse how particular structural
changes in the enzyme structures might modify their catalytic properti
es. However, despite the many available kinetic, structural and mutage
nesis data, the factors explaining the diversity of the specificity pr
ofiles of class A beta-lactamases and their amazing catalytic efficien
cy have not been thoroughly elucidated. The detailed understanding of
these phenomena constitutes the cornerstone for the design of future g
enerations of antibiotics.